Cost-effectiveness of amyloid-targeting therapies in a memory clinic population; a simulation study

The study evaluated the cost-effectiveness of new amyloid-targeting therapies (ATT) for patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. Using a computer simulation model, treatment scenarios were simulated over the patient's lifetime. Therapy without treatment effect waning resulted in 0.72 additional quality-adjusted life years and 28,502 euros in additional costs per person compared to standard care. At a price of 22,600 euros per year, the cost-effectiveness was 39,745 euros per quality-adjusted life year without waning and 151,016 euros with 20% annual waning. At a willingness-to-pay threshold of 20,000 euros per quality-adjusted life year, the therapy price should not exceed 10,500 euros without treatment effect waning. The study concludes that the cost-effectiveness of these therapies is strongly dependent on whether the treatment effect is maintained after the 18-month treatment period.